Pregabalin Capsule
Product Images NDC 68788-7522

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Caps 75mg 30s Count

Label for Pregabalin Capsules 75 mg by Preferred Pharmaceuticals, Inc. The label indicates the generic drug name Pregabalin and states it is generic for Lyrica. It includes dosing instructions in English and Spanish to take capsules at specified hourly intervals. The label mentions manufacturer ScieGen Pharmaceuticals, Inc., storage conditions, and has spaces for lot number, expiration date, batch number, and product number.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. Each group is represented by a different line style, illustrating differences in pain improvement among the groups.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent improvement in pain from baseline to the percent of patients improved for Pregabalin 100 mg three times a day versus placebo. The graph shows two curves, one for Pregabalin and one for placebo, illustrating a higher percentage of patient improvement with Pregabalin over a range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent improvement in pain from baseline among patients treated with different dosages of Pregabalin (75 mg, 150 mg, and 300 mg twice daily) compared to placebo. The y-axis represents the percent of patients improved, while the x-axis shows the percent improvement in pain, ranging from 0 to 100. Higher doses of Pregabalin correlate with greater patient improvement percentages.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph displays three lines depicting patient response rates over a range of pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline. The chart compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo, showing trends in patient response to pain relief.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates in two clinical studies labeled Study E1 and Study E3 for different doses of pregabalin versus placebo. The vertical axis shows responder rate percentages, with bars indicating higher responder rates at increased pregabalin doses compared to placebo. Study E1 shows rates from 14% (placebo) up to 51% (600 mg/day), and Study E3 shows rates from 9% (placebo) up to 49% (600 mg/day). Values include sample sizes and dosage frequency labels.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day. The graph compares four studies (E1 BID, E2 TID, E3 BID, E3 TID) with data points marked and significant p-values indicated. Dose ranges from 0 to 600 mg/day, and seizure reduction ranges from 0 to 60 percent. Placebo dose is marked as zero.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares four lines representing pregabalin 800 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, depicting patient improvement trends across different dosage levels.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph depicting the estimated percentage of subjects without LTR (likely loss to follow-up or related term) over a 180-day period. Two lines compare Pregabalin to placebo, with the Pregabalin group showing a higher percentage of subjects without LTR throughout the duration.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percentage of subjects improved from baseline to week 12 between two groups: Pregabalin and Placebo. The x-axis represents the percent improved, while the y-axis shows the percent of subjects improved. Pregabalin is depicted with a solid line, demonstrating higher improvement rates than the placebo, which is shown with a dashed line.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over time from baseline to week 16, showing two lines representing Pregabalin and Placebo. The x-axis indicates percent improved from baseline while the y-axis shows percent of subjects improved. The Pregabalin line is consistently above the Placebo line, indicating higher improvement rates.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

An equation panel showing the formula to calculate creatinine clearance (CLcr). It includes variables for age, weight, serum creatinine, and a multiplication factor for female patients. The text is clear and formatted mathematically.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, the active ingredient in Pregabalin capsules 75 mg by Preferred Pharmaceuticals, Inc. The diagram shows the molecular structure including amine and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.